BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $GSK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06567782-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:AZUR-4 readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxali
 platin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mism
 atch Repair Proficient (MMRp)/Microsatelli…\n\nPrimary completion date: 
 2026-11-23 (estimated)\nOriginally planned: 2028-09-07 (-21.5 months)\nPha
 se 2 · Oncology · Neoplasms\, Colon\nEnrollment: 120 · Sites: 33\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT06567782\nhttps://clinicaltrials.gov/study/NCT06567782
URL:https://datacutoff.com/radar.html?nct=NCT06567782
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06693895-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:Investigational varicella vaccine readout (P3) · GlaxoSmithKline $
 GSK
DESCRIPTION:A Study on the Safety of an Investigational Chickenpox Vaccine\
 , When Given to Healthy Children\, 12 to 15 Months of Age\n\nPrimary compl
 etion date: 2026-11-23 (estimated)\nOriginally planned: 2026-07-13 (+4.4 m
 onths)\nPhase 3 · Infectious · Chickenpox\nEnrollment: 750 · Sites: 46\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT06693895\nhttps://clinicaltrials.gov/study/NCT066938
 95
URL:https://datacutoff.com/radar.html?nct=NCT06693895
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596199-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:dTpa readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A Study on the Immune Response and Safety of a Combined Vaccine
  Against Diphtheria\, Tetanus and Acellular Pertussis (dTpa) in Japanese H
 ealthy Pregnant Women\n\nPrimary completion date: 2026-11-23 (estimated)\n
 Phase 3 · Infectious · Diphtheria-Tetanus-acellular Pertussis Vaccines\n
 Enrollment: 102 · Sites: 21\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07596199\nhttps://clini
 caltrials.gov/study/NCT07596199
URL:https://datacutoff.com/radar.html?nct=NCT07596199
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03441113-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Momelotinib readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:Extended Access of Momelotinib in Adults With Myelofibrosis\n\n
 Primary completion date: 2026-12-11 (estimated)\nOriginally planned: 2020-
 06 (+78.3 months)\nPhase 2 · Oncology · Primary Myelofibrosis\nEnrollmen
 t: 237 · Sites: 112\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //trialsonar.netlify.app/radar.html?nct=NCT03441113\nhttps://clinicaltrial
 s.gov/study/NCT03441113
URL:https://datacutoff.com/radar.html?nct=NCT03441113
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317311-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:RUBY-J readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of Dostarlimab in Combination With Carboplatin-paclitax
 el in Japanese Participants With Primary Advanced or Recurrent Endometrial
  Cancer\n\nPrimary completion date: 2026-12-14 (estimated)\nOriginally pla
 nned: 2026-07-15 (+5.0 months)\nPhase 2 · Oncology · Carcinoma\nEnrollme
 nt: 41 · Sites: 15\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /trialsonar.netlify.app/radar.html?nct=NCT06317311\nhttps://clinicaltrials
 .gov/study/NCT06317311
URL:https://datacutoff.com/radar.html?nct=NCT06317311
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806137-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Investigational varicella vaccine readout (P3) · GlaxoSmithKline $
 GSK
DESCRIPTION:A Study on the Immune Response and Safety of the Second Dose of
  an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Mo
 nths After a First Dose at 12 to 15 Months…\n\nPrimary completion date: 
 2026-12-14 (estimated)\nPhase 3 · Infectious · Chickenpox\nEnrollment: 6
 00 · Sites: 6\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://tria
 lsonar.netlify.app/radar.html?nct=NCT06806137\nhttps://clinicaltrials.gov/
 study/NCT06806137
URL:https://datacutoff.com/radar.html?nct=NCT06806137
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06740630-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Investigational varicella vaccine_Lot 1 readout (P3) · GlaxoSmithK
 line $GSK
DESCRIPTION:A Study on the Immune Response and Safety of an Investigational
  Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age\
 n\nPrimary completion date: 2026-12-25 (estimated)\nPhase 3 · Infectious 
 · Chickenpox\nEnrollment: 1840 · Sites: 97\n\nPrimary completion = last 
 participant's primary-endpoint data collected\; topline results usually fo
 llow weeks to months later. Sponsor-reported\, often an estimate. Not inve
 stment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0674063
 0\nhttps://clinicaltrials.gov/study/NCT06740630
URL:https://datacutoff.com/radar.html?nct=NCT06740630
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04641247-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Niraparib readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Long-term Treatment Extension Study of Niraparib in Participa
 nts Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
 \n\nPrimary completion date: 2026-12-28 (estimated)\nOriginally planned: 2
 025-11-27 (+13.0 months)\nPhase 2 · Oncology · Ovarian Neoplasms\, Breas
 t Neoplasms\nEnrollment: 37 · Sites: 25\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04641247\nh
 ttps://clinicaltrials.gov/study/NCT04641247
URL:https://datacutoff.com/radar.html?nct=NCT04641247
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645248-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:HFA-152a readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A Study to Compare Safety of 4 Weeks Exposure to Propellants Hy
 drofluoroalkane 1\,1-difluoroethane (HFA-152a) and HFA-1\,1\,1\,2-tetraflu
 oroethane (134a)\n\nPrimary completion date: 2026-12-28 (estimated)\nOrigi
 nally planned: 2027-02-25 (-1.9 months)\nPhase 3 · Respiratory · Asthma\
 nEnrollment: 110 · Sites: 20\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07645248\nhttps://clin
 icaltrials.gov/study/NCT07645248
URL:https://datacutoff.com/radar.html?nct=NCT07645248
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07092865-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Adjuvanted RSVPreF3 vaccine readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study Evaluating Persistence of the Immune Response of the Ad
 juvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immu
 ne Response Following Revaccination in Adu…\n\nPrimary completion date: 
 2027-01-12 (estimated)\nPhase 2 · Infectious · Respiratory Syncytial Vir
 us Infections\nEnrollment: 168 · Sites: 38\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07092865
 \nhttps://clinicaltrials.gov/study/NCT07092865
URL:https://datacutoff.com/radar.html?nct=NCT07092865
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757102-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:FF/UMEC/VI readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A Study to Compare the Efficacy\, Safety and Tolerability of FF
 /UMEC/VI With FF/VI in 12-17-year-olds With Asthma\n\nPrimary completion d
 ate: 2027-01-26 (estimated)\nOriginally planned: 2024-10-10 (+27.5 months)
 \nPhase 3 · Respiratory · Asthma\nEnrollment: 138 · Sites: 67\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT05757102\nhttps://clinicaltrials.gov/study/NCT05757102
URL:https://datacutoff.com/radar.html?nct=NCT05757102
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671001-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:GLIDE readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of Depemokimab in Participants of 6 to 11 Years of Age\
 n\nPrimary completion date: 2027-03-01 (estimated)\nOriginally planned: 20
 29-03-19 (-24.6 months)\nPhase 3 · Respiratory · Asthma\nEnrollment: 34 
 · Sites: 3\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://trialso
 nar.netlify.app/radar.html?nct=NCT07671001\nhttps://clinicaltrials.gov/stu
 dy/NCT07671001
URL:https://datacutoff.com/radar.html?nct=NCT07671001
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519395-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:BALANCE readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study to Investigate Abdominal Symptoms With Camlipixant Comp
 ared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-
 D) and Irritable Bowel Syndrome - Mixed (I…\n\nPrimary completion date: 
 2027-03-09 (estimated)\nPhase 2 · GI·Renal·Heme · Irritable Bowel Synd
 rome\nEnrollment: 420 · Sites: 114\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07519395\nhttps:
 //clinicaltrials.gov/study/NCT07519395
URL:https://datacutoff.com/radar.html?nct=NCT07519395
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05087056-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270310
DTEND;VALUE=DATE:20270311
SUMMARY:MenABCWY vaccine readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:Safety\, Tolerability\, and Immunogenicity of MenABCWY Administ
 ered on Different Dosing Schedules in Healthy Adolescents\n\nPrimary compl
 etion date: 2027-03-10 (estimated)\nOriginally planned: 2026-05-29 (+9.4 m
 onths)\nPhase 2 · Infectious · Meningitis\, Meningococcal\nEnrollment: 3
 05 · Sites: 30\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT05087056\nhttps://clinicaltrials.gov
 /study/NCT05087056
URL:https://datacutoff.com/radar.html?nct=NCT05087056
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517875-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:ODYSSEY readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:Study of Momelotinib in Combination With Luspatercept in Partic
 ipants With Transfusion Dependent Myelofibrosis\n\nPrimary completion date
 : 2027-03-16 (estimated)\nOriginally planned: 2026-08-14 (+7.0 months)\nPh
 ase 2 · Cardio-Met · Primary Myelofibrosis\, Myelofibrosis\; Primary Mye
 lofibrosis\; Post-polycythemia Ver…\nEnrollment: 68 · Sites: 33\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT06517875\nhttps://clinicaltrials.gov/study/NCT06517875
URL:https://datacutoff.com/radar.html?nct=NCT06517875
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497504-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270422
DTEND;VALUE=DATE:20270423
SUMMARY:B-Focus readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:Study of Bepirovirsen in Participants Living With Human Immunod
 eficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)\n\nPrima
 ry completion date: 2027-04-22 (estimated)\nOriginally planned: 2027-01-27
  (+2.8 months)\nPhase 2 · Infectious · Hepatitis B\nEnrollment: 153 · S
 ites: 51\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://trialsonar
 .netlify.app/radar.html?nct=NCT06497504\nhttps://clinicaltrials.gov/study/
 NCT06497504
URL:https://datacutoff.com/radar.html?nct=NCT06497504
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07036159-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:RTS\,S/AS01E vaccine readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study to Assess the Safety and Immunogenicity of a Vaccine Ag
 ainst Malaria in Healthy Children Aged 5-60 Months\n\nPrimary completion d
 ate: 2027-04-23 (estimated)\nPhase 2 · Infectious · Malaria\nEnrollment:
  238 · Sites: 2\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tr
 ialsonar.netlify.app/radar.html?nct=NCT07036159\nhttps://clinicaltrials.go
 v/study/NCT07036159
URL:https://datacutoff.com/radar.html?nct=NCT07036159
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201051-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:GSK3862995B readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study to Assess the Effectiveness and Safety of GSK3862995B i
 n Adults With Bronchiectasis\n\nPrimary completion date: 2027-05-04 (estim
 ated)\nOriginally planned: 2027-03-15 (+1.6 months)\nPhase 2 · Respirator
 y · Bronchiectasis\nEnrollment: 363 · Sites: 134\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 7201051\nhttps://clinicaltrials.gov/study/NCT07201051
URL:https://datacutoff.com/radar.html?nct=NCT07201051
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06666491-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Tafenoquine readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:An Interventional Study to Compare the Efficacy and Safety of T
 afenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Ch
 loroquine (CQ) for the Treatment of P. Viv…\n\nPrimary completion date: 
 2027-05-14 (estimated)\nOriginally planned: 2026-04-15 (+12.9 months)\nPha
 se 3 · Infectious · Malaria\, Vivax\nEnrollment: 324 · Sites: 5\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT06666491\nhttps://clinicaltrials.gov/study/NCT06666491
URL:https://datacutoff.com/radar.html?nct=NCT06666491
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537414-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:B-UNITED readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP
 /TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatit
 is B (CHB)\n\nPrimary completion date: 2027-05-31 (estimated)\nOriginally 
 planned: 2028-01-04 (-7.2 months)\nPhase 2 · Infectious · Chronic Hepati
 tis B Virus Infection\, Hepatitis B\nEnrollment: 283 · Sites: 80\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT06537414\nhttps://clinicaltrials.gov/study/NCT06537414
URL:https://datacutoff.com/radar.html?nct=NCT06537414
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851246-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:mRNA Seasonal Flu vaccine readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A Study to Evaluate the Immune Response and Safety of a Vaccine
  Against Influenza in Adults 18-64 Years of Age\n\nPrimary completion date
 : 2027-07-09 (estimated)\nPhase 3 · Infectious · Influenza\, Human\nEnro
 llment: 3000 · Sites: 12\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://trialsonar.netlify.app/radar.html?nct=NCT07851246\nhttps://clinical
 trials.gov/study/NCT07851246
URL:https://datacutoff.com/radar.html?nct=NCT07851246
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847867-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:MIDAS readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of Momelotinib in Participants With Low-risk Myelodyspl
 astic Syndrome\n\nPrimary completion date: 2027-07-14 (estimated)\nOrigina
 lly planned: 2027-04-05 (+3.3 months)\nPhase 2 · Oncology · Myelodysplas
 tic Syndromes\nEnrollment: 80 · Sites: 39\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06847867\
 nhttps://clinicaltrials.gov/study/NCT06847867
URL:https://datacutoff.com/radar.html?nct=NCT06847867
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650084-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:CALM-2 readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adult
 s With Refractory Chronic Cough - China Extension\n\nPrimary completion da
 te: 2027-08-27 (estimated)\nPhase 3 · Respiratory · Refractory Chronic C
 ough\nEnrollment: 75 · Sites: 38\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT07650084\nhttps://
 clinicaltrials.gov/study/NCT07650084
URL:https://datacutoff.com/radar.html?nct=NCT07650084
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545681-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:GSK3772701 600 mg readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adu
 lt Patients With Uncomplicated P. Falciparum Malaria\n\nPrimary completion
  date: 2027-10-08 (estimated)\nOriginally planned: 2027-07-22 (+2.6 months
 )\nPhase 2 · Infectious · Malaria\, Falciparum\nEnrollment: 70 · Sites:
  2\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netli
 fy.app/radar.html?nct=NCT07545681\nhttps://clinicaltrials.gov/study/NCT075
 45681
URL:https://datacutoff.com/radar.html?nct=NCT07545681
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640049-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271024
DTEND;VALUE=DATE:20271025
SUMMARY:China AZUR-1 readout (P2) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of Dostarlimab in Participants With Untreated Locally A
 dvanced Rectal Cancer in China\n\nPrimary completion date: 2027-10-24 (est
 imated)\nOriginally planned: 2028-12-31 (-14.3 months)\nPhase 2 · Oncolog
 y · Neoplasms\, Rectal\nEnrollment: 23 · Sites: 9\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 06640049\nhttps://clinicaltrials.gov/study/NCT06640049
URL:https://datacutoff.com/radar.html?nct=NCT06640049
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202546-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:VH4524184 readout (P2) · ViiV Healthcare $GSK
DESCRIPTION:A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatmen
 t Naïve Persons With HIV-1 (INNOVATE Study)\n\nPrimary completion date: 2
 027-10-28 (estimated)\nOriginally planned: 2027-06-11 (+4.6 months)\nPhase
  2 · Infectious · HIV Infections\nEnrollment: 186 · Sites: 125\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT07202546\nhttps://clinicaltrials.gov/study/NCT07202546
URL:https://datacutoff.com/radar.html?nct=NCT07202546
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05334368-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271029
DTEND;VALUE=DATE:20271030
SUMMARY:DESTINY readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:Depemokimab in Participants With Hypereosinophilic Syndrome\, E
 fficacy\, and Safety Trial\n\nPrimary completion date: 2027-10-29 (estimat
 ed)\nOriginally planned: 2025-05-02 (+29.9 months)\nPhase 3 · GI·Renal·
 Heme · Hypereosinophilic Syndrome\nEnrollment: 110 · Sites: 60\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT05334368\nhttps://clinicaltrials.gov/study/NCT05334368
URL:https://datacutoff.com/radar.html?nct=NCT05334368
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099898-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan (Ris-Rez) readout (P3) · GlaxoSmithKline $GSK
DESCRIPTION:A Study of GSK5764227 in Participants With Relapsed Small Cell 
 Lung Cancer (SCLC) [EMBOLD SCLC-301]\n\nPrimary completion date: 2027-11-0
 5 (estimated)\nOriginally planned: 2026-09-08 (+13.9 months)\nPhase 3 · O
 ncology · Neoplasms\, Lung\nEnrollment: 420 · Sites: 148\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07099898\nhttps://clinicaltrials.gov/study/NCT07099898
URL:https://datacutoff.com/radar.html?nct=NCT07099898
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
